AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

By Nikita Chaurasia  | Date: 2021-03-23

AstraZeneca COVID-19 vaccine found to be 79% effective in U.S. trials

The COVID-19 vaccine co-developed by AstraZeneca Plc, a British-Swedish multinational biotechnology company, and scientists at Oxford University, has reportedly passed the U.S. clinical trials with 79% effectiveness in preventing symptomatic disease in over 32,000 participants.

AstraZeneca announced that it would keep analyzing data and make relevant provisions in a bid to request emergency use authorization (EUA) in the United States in the upcoming weeks. The move, if approved by authorities, will make the vaccine available for American citizens.

The shot has already been widely administered across several European countries. The U.S. trials, however, involved a sample size study of 32,000 participants - the largest-ever number of people to be studied for the effectiveness of AstraZeneca’s COVID-19 vaccine.

The study could reinstate public confidence in the vaccine, after speculations regarding its efficacy arose following serious blood-clotting issues in a small number of individuals in Europe who received the shot, sources claimed. The trials conducted in the U.S. found no increased risk of serious blood clotting among the vaccinated population.

AstraZeneca reportedly mentioned that the vaccine had an 80% rate of efficacy among elder participants aged 65 years and above.

In the past few weeks, blood clotting fears led several European countries, such as Italy and Germany, to temporarily discontinue the use of the vaccine. However, most countries resumed its usage after European and U.K. medicine authorities reiterated the shot's effectiveness despite the rare incidences of blood clotting, which were not proven to be connected to the vaccine.

The EU regulators claimed to not have ruled out the possibility of blood clots but emphasized that the vaccine is a shield preventing severe symptoms and death and that its benefits outweigh risks.

In other news, AstraZeneca has recently cut the number of doses delivered to the EU after blaming production delays in the Netherland and Belgium. The EU had imposed export controls for coronavirus vaccines in March this year to stop a consignment of 2,50,000 doses that were to be shipped from Italy to Australia.

Source Credits –

https://www.marketwatch.com/story/astrazeneca-us-covid-vaccine-trial-79-effective-2021-03-22?link=MW_latest_news

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

By Nikita Chaurasia

British/American hydrogen-electric aircraft developer, ZeroAvia has wholly purchased HyPoint, a hydrogen fuel cell system provider, to strengthen its hydrogen-electric product portfolio. As per sources, ZeroAvia is developing powertrains for hydro...

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

By Nikita Chaurasia

French luxury fashion house well-recognized for its perfumes and tweed suits, Chanel, has reportedly unveiled ­sustainability-linked bonds, or SLBs, to combat climate change two years ago when the firm was in need to borrow money. The investor...

NLP Logix Partners and Databricks team up for Lakehouse Platform

NLP Logix Partners and Databricks team up for Lakehouse Platform

By Nikita Chaurasia

NLP Logix, a well-known predictive modeling and machine learning leader, has recently announced that it has entered into a partnership with Databricks, an American enterprise software company, to drive business value by deploying data and artificial ...

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

By Nikita Chaurasia

Elliptic Labs, a global AI software company, has reportedly entered into a new agreement with Xiaomi, one of the third-largest smartphone manufacturers across the globe. With this agreement, Xiaomi will continue to leverage INNER BEAUTY, the AI Vi...

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...